San Diego-centered Viking Therapeutics marked itself as a serious competitor in the weight loss drug market place in February soon after revealing promising information from a mid-phase trial of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs when specified as being a weekly injection and in March the com